The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis - Takeaways - MDSpire

The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis

  • By

  • Jinxia Hao

  • Tongxin Zhang

  • Juan Ren

  • Xiaoning Wang

  • June 19, 2026

  • 0 min

Share

  • 1

    Rituximab administration during conditioning may reduce EBV viremia incidence post-haplo-HSCT compared to controls without rituximab.

  • 2

    The study involved 100 patients with acute leukemia or myelodysplastic syndrome undergoing haplo-HSCT.

  • 3

    The R group showed a lower incidence of acute graft-versus-host disease (aGVHD) compared to the control group.

  • 4

    No significant differences were found in CMV viremia, chronic GVHD, or 100-day non-relapse mortality between the two groups.

  • 5

    The study suggests rituximab may be an effective strategy for preventing EBV reactivation in haplo-HSCT, pending further validation.

Original Source(s)

The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis

  • by Jinxia Hao, Tongxin Zhang, Juan Ren, Xiaoning Wang

  • June 19, 2026

Related Content

Transplant indications, guidelines and recommendations: Caveat Emptor

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

From One Stem Cell to Millions of Cancer Killers

A three-step engineering strategy generates vast numbers of potent NK immune cells – potentially slashing the cost and scaling of cancer immunotherapy

  • April 1, 2026

  • 1 min